Government measures to reduce the cost of pharmaceuticals by promoting a consumption shift towards generic drugs and recentralising drug procurement The new method for calculating drug reimbursement is hindering sales of innovative drugs Problems in healthcare sector financing, particularly state hospital drug purchasing The costs of modernisation potentially derailing the recent rapid improvement of the domestic regulatory infrastructure Introduction of prescribing restrictions as a possibility Roll-out of co-payments to negatively impact volume sales of expensive medicines in favour of cheaper products Long term viability of healthcare system in question due to ageing population and falling birth rates ...
...� Business Monitor International Ltd Page - Pharmaceutical SWOT Analysis - Continued EU accession stimulating rapid regulatory reforms, dramatically improving the market environment for foreign companies. High growth potential in private healthcare sector. ...High growth potential in private healthcare sector. Pharmaceuticals growth led by the low cost generic and OTC drug sectors, given the increased health awareness and a desire to seek treatment outside the cash-strapped state sector. Long term uptake in patented drugs expected as disease burden shifts towards chronic and non-communicable diseases Sustained, robust economic growth will improve consumer picture for OTC and generic medicines ...Pharmaceuticals growth led by the low cost generic and OTC drug sectors, given the increased health awareness and a desire to seek treatment outside the cash-strapped state sector. Long term uptake in patented drugs expected as disease burden shifts towards chronic and non-communicable diseases Sustained, robust economic growth will improve consumer picture for OTC and generic medicines
...Local drug manufacturing industry now largely in private and foreign hands. Consolidation of the wholesale and retail environment, signalling maturing environment. ...Consolidation of the wholesale and retail environment, signalling maturing environment. More transparent wholesale and retail sectors providing easier entry and greater marketing potential for manufacturers. Fast-tracking registration available for urgently needed drugs. Comparatively high market share for patented products against neighbouring markets. Healthcare market reform, including the introduction of co-payments will increase access to higher value drugs, though as a proportion of total it is expected to drop.
...